NY-DOOLA
12.5.2022 14:32:10 CEST | Business Wire | Press release
doola announced today that they have launched a banking product for global businesses that will allow founders to open a US bank account, remotely, from any continent, with no US Social Security Number required. Founders globally can now register an LLC, DAO LLC, or C Corp through doola, get an EIN (employer identification number) from the IRS with doola, and open a US bank account with doola. It doesn’t stop there: doola also provides ongoing compliance with the state and IRS to keep companies compliant, making doola an all-in-one platform for founders to launch, maintain and grow their US business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509006242/en/
doola's banking product will include a business checking account along with domestic and international wire transfers, virtual cards, a physical debit card that is mailed to founders anywhere in the world, tools and features to seamlessly integrate with your US entity, and more.
“ For any business, whether it's a venture-backed SaaS startup with a Delaware C Corp or a solopreneur bootstrapping an e-commerce business, having a trustworthy, stable, and scalable banking + payments stack is critical. Through doola, international founders can seamlessly access the US financial ecosystem, including US banking, US payment solutions, US venture capital, and more,” said Jacqueline Reses , an investor in doola, Chairman of the Economic Development Council at Federal Reserve Bank of San Francisco, and Former Head of Square Capital.
Arjun Mahadevan, CEO, doola said, “From day 1, we’ve known that doola is not a formation service. We’re a fintech company. Founders globally don’t actually want a company; they want a way to accept payments globally in the US dollar, or accept investment from US investors. doola Banking makes our platform the fastest way to go from formation to accepting your first payment/deposit globally. Why? Because we do it all in-house. It’s click button, get company + EIN + bank account, and ongoing compliance including state + IRS filings are taken care of. As our customers like to say, we’re a Business-in-a-Box.”
About doola
doola (formerly StartPack, YCombinator S20) helps global web2 and web 3 entrepreneurs form U.S. LLCs, C Corps, and DAO LLCs by supporting customers through the incorporation process so they can confidently collect payments, build credibility, stay legal, and make more money. doola provides company formation, an EIN, a U.S. address and bank account, access to U.S. payments, a free tax consultation, U.S. tax support, a phone number, $50,000 in startup perks, and more. Today, hundreds of companies have launched with doola, and these founders didn't need a U.S. social security number to benefit from doola's products and services. The company is led by Arjun Mahadevan, a former Growth Product Manager at Dropbox, who is a U.S. immigrant and JP Pincheira, a full stack engineer who is a foreign founder from Chile. (HQ: New York City)
doola is a financial technology company and is not a bank. Banking services provided by Piermont Bank; Member FDIC. The doola Visa® Debit Card is issued by Piermont Bank pursuant to a license from Visa U.S.A. Inc. and may be used everywhere Visa debit cards are accepted.
Related Links
Website: https://www.doola.com/banking
Twitter: https://twitter.com/doolaHQ
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509006242/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom